Search Results for “FDA” – Page 165 – media

One More Approval for Merck’s Keytruda

On Wednesday, a day after Keytruda got the thumbs up for cervical cancer, the drug was approved for treatment of a rare form of non-Hodgkins lymphoma patients who cancer returned after at least two previous treatment lines. Last year, Keytruda also got an indication for classical Hodgkin lymphoma.
- Source: Fierce Pharma
- 711
- June 15, 2018
cancer Merck New Approvals non-Hodgkin lymphoma
Airo CT Imaging For Pediatrics

It has been reported that the FDA has granted the approval of Mobius Imaging, LLC based Airo CT imaging utilization for pediatric patients. These pediatric patients can receive the clinical benefits of Airo CT imaging for diagnostic and intraoperative procedures hereafter.
- Source: MPO mag
- 772
- June 13, 2018
CT scanner medical device New Approvals
Emergent BioSolutions to Invest $50M for Expansion

Emergent BioSolutions, Gaithersburg, Maryland-based Biopharmaceutical Company announced that it will invest $50 million for the next three years to expand the manufacturing capacity for its Camden fill-finish in Baltimore facility. By the time the project has been completed in three years, it is expected to add up 60 jobs.
- Source: FiercePharma
- 778
- June 11, 2018
biopharmaceutical Company Insight
Hospira Inc. Recalls Opioid Antidote Naloxone

According to the FDA, if the antidote drugs are used on a patient, they could suffer from “allergic reactions, local irritation” and a wide number of cardiovascular issues, including restriction of blood supply to tissues. The FDA stated that there has not yet been any reports of patient harm from Naloxone.
- Source: Ddu
- 604
- June 7, 2018
Company Insights FDA opioid
Lynparza and Zytiga Combo Effective Against Prostate Cancer

Along with new drug partner Merck, the British drugmaker displayed results showing that adding Lynparza to Johnson & Johnson prostate cancer fighter Zytiga was a more potent disease-fighter than Zytiga alone. As compared to a time-frame of 8.2 months for solo Zytiga, the combo effectively prevented disease progression for 13.8 months.
- Source: Ddu
- 757
- June 6, 2018
AstraZeneca Clinical Trials Company Insight prostate cancer
New Hope For Osteoporosis, SLIT3 Protein Molecule To Advance Bone Blood Vessels

Weill Cornell’s Medicine scientist claim to have discovered a new treatment for osteoporosis, which targets the blood vessels inside of bone, a molecule that promotes the growth of those blood vessels and reverses the weakening of bones and helps fracture, heals.
- Source: Ddu
- 645
- May 29, 2018
osteoporosis Researches
Mercks to Lead Squamous Lung Cancer Treatment With Keytruda

Pharma giant Merck & Co. revealed Keytruda had perfectly completed its final-stage research on the drug for previously untreated patients with skin cancer, who represent about 25% to 30% of the overall market.
- Source: Ddu
- 627
- May 24, 2018
cancer Company Insight Merck
Health-Check-Up Through Sweat Monitoring Wearable Device

Cincinnati-based startup Eccrine System has developed a health wearable devices called Sweatronics which tracks your health using sweat. Other bodily fluids like urine and blood contain plenty of the body information’s but are not as easy to collect. However, Sweatronics needs only sweat samples that is produces automatically while working or even sleeping.
- Source: Ddu
- 1,658
- May 24, 2018
digital health mHealth New Approvals
Opt for Cancer Drug to forgo Tuberculosis

More than one-quarter of the world’s population were constantly getting affected with the one of the world’s oldest and deadliest disease named Tuberculosis (TB). In spite of 6-9 months antibiotic therapy, it’s very difficult to treat tuberculosis. That’s why researchers throughout the world were trying to find the faster ways of cure.
- Source: Ddu
- 578
- May 18, 2018
cancer Researches tuberculosis
LifePlus announces glucose monitoring wearable

The company announced that the innovative product, whose technological details are not known yet, is undergoing clinical trials in five cities across the world. The patent-pending invention is based on open standards software and cloud-based analytics. The system gives users real-time notifications and cloud-based AI solutions.
- Source: Ddu
- 973
- May 18, 2018
Clinical Trials mHealth wearables

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.